Methotrexate for Inflammatory Bowel Diseases - New Developments | Zendy

Hans Herfarth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Methotrexate for Inflammatory Bowel Diseases - New Developments

Author(s) -

Hans Herfarth

Publication year - 2016

Publication title -

digestive diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.879

H-Index - 66

eISSN - 1421-9875

pISSN - 0257-2753

DOI - 10.1159/000443129

Subject(s) - medicine , methotrexate , inflammatory bowel disease , ulcerative colitis , crohn's disease , drug , disease , inflammatory bowel diseases , immunology , gastroenterology , pharmacology

Methotrexate (MTX) is an established therapy for patients with steroid-dependent Crohn's disease (CD). MTX is also frequently used in combination with anti-TNF agents to suppress anti-drug antibody formation. It has been suggested in the past that MTX lacks any clinical effectiveness in patients with ulcerative colitis (UC); however, newer data at least partially contradict this assumption. The following review will discuss recent data for the use of MTX in CD, UC and in combination with anti-TNF agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research